Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.

Abstract

Interleukin-2 (IL-2) and beta-interferon (beta-IFN) are cytokines with profound immunobiological effects on T-cell and natural killer (NK) cell activity; IL-2 also induces lymphokine-activated killer (LAK) cell cytotoxicity in humans. Both lymphokines induce antineoplastic activity against several refractory tumors. This Phase I study of 50 patients… (More)

Topics

  • Presentations referencing similar topics